EUVIMEDOpdag EUVIMED
Crossref

Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis

Lawrence F Eichenfield, Jonathan I Silverberg, Adelaide A Hebert, Raj Chovatiya, Philip M Brown, Kimberly A McHale, David S Rubenstein, Anna M Tallman

Journal of Drugs in Dermatology · 2024

DOI: 10.36849/jdd.8026 ↗

At a glance

Journal article in Journal of Drugs in Dermatology, 2024. Written by Lawrence F Eichenfield and 7 co-authors. Major MEDLINE topics: Dermatitis, Atopic, Stilbenes. Cited 8 times so far (Crossref).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Atopic dermatitis (AD) is a chronic relapsing–remitting disease with a multifactorial etiology involving epidermal barrier and immunologic dysfunction. Topical therapies form the mainstay of AD treatment, but options are limited by adverse effects and restrictions on application site, duration, and extent of use. Tapinarof (VTAMA; Dermavant Sciences, Inc.) is a first-in-class, non-steroidal, topical aryl hydrocarbon receptor (AhR) agonist approved for the treatment of plaque psoriasis. AhR is a ligand-dependent transcription factor with wide-ranging roles, including regulation of homeostasis and immune response in skin cells. AhR expression and signaling are altered in many inflammatory skin diseases, and clinical trials with tapinarof have validated AhR as a therapeutic target capable of delivering significant efficacy. Tapinarof cream 1% once daily demonstrated efficacy versus vehicle in adults and adolescents with AD and is being investigated in the ADORING trials for the treatment of AD in adults and children down to 2 years of age. J Drugs Dermatol. 2024;23(2):23-28. doi:10.36849/JDD.8026.

Subjects

MeSH terms (MEDLINE)

Dermatitis, AtopicStilbenesHumansReceptors, Aryl HydrocarbonResorcinolsSkin

Substances

Receptors, Aryl HydrocarbonResorcinolsStilbenestapinarof

Cite

APA

Eichenfield, L. F., Silverberg, J. I., Hebert, A. A., Chovatiya, R., Brown, P. M., McHale, K. A., Rubenstein, D. S., & Tallman, A. M. (2024). Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.8026

Vancouver

Eichenfield LF, Silverberg JI, Hebert AA, Chovatiya R, Brown PM, McHale KA, et al. Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis. Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.8026

BibTeX
@article{Eichenfield2024,
  author = {Eichenfield, Lawrence F and Silverberg, Jonathan I and Hebert, Adelaide A and Chovatiya, Raj and Brown, Philip M and McHale, Kimberly A and Rubenstein, David S and Tallman, Anna M},
  title = {Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis},
  journal = {Journal of Drugs in Dermatology},
  year = {2024},
  doi = {10.36849/jdd.8026}
}
Start for free →